Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Atul Dandekar also recently made the following trade(s):

• On Tuesday, December 30th, Atul Dandekar sold 100 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.36, for a total transaction of $4,036.00.

Maze Therapeutics Stock Up 3.4%

Maze Therapeutics stock traded up $1.38 during mid-day trading on Wednesday, hitting $41.43. 394,842 shares of the company’s stock were exchanged, compared to its average volume of 325,768. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $43.29. The firm has a market capitalization of $1.99 billion and a P/E ratio of -1.98. The company’s 50 day simple moving average is $36.34 and its 200-day simple moving average is $24.46.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MAZE. Ameritas Investment Partners Inc. lifted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics during the third quarter worth about $52,000. CWM LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth approximately $28,000. Finally, Legal & General Group Plc lifted its stake in Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after acquiring an additional 3,371 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have issued reports on MAZE shares. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price target on the stock. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Guggenheim reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Friday, December 19th. BTIG Research boosted their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, HC Wainwright upped their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $43.38.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.